Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Global Retirement Partners purchased 1,564 Regeneron shares valued at approximately $975,000 during the second quarter. Institutional investors and hedge funds collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 versus estimates of $10.16 and revenue of $4.29 billion, up 16.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $801.70.
• Directors sold a combined 1,200 shares under pre-arranged Rule 10b5-1 plans, while ongoing litigation related to the failed fianlimab-Libtayo trial could create legal, reputational and commercial risks.

Global Retirement Partners LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,564 shares of the biopharmaceutical company's stock, valued at approximately $975,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Orbimed Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth about $11,358,000. Lockheed Martin Investment Management Co. purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $2,702,000. National Pension Service grew its holdings in shares of Regeneron Pharmaceuticals by 29.8% in the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company's stock valued at $278,636,000 after purchasing an additional 82,853 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $10,472,000. Finally, Contravisory Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $6,327,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at $482,400. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 over the last ninety days. 6.97% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Barclays lowered their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a research note on Thursday, April 30th. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $801.70.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Leerink raises price target: Leerink Partners increased its REGN price target from $641 to $824, implying modest additional upside. However, the firm retained a “market perform” rating, suggesting limited conviction in a stronger near-term advance. Benzinga analyst price target report
• Neutral Sentiment: Class-action deadline approaches: Several law firms, including Pomerantz, Hagens Berman, Faruqi & Faruqi, and The Schall Law Firm, reminded investors of a September 14, 2026 deadline to seek lead-plaintiff status in a securities lawsuit. These announcements largely repeat previously reported information and do not represent a new financial or regulatory finding. Pomerantz investor alert
• Negative Sentiment: Litigation highlights clinical-trial concerns: The lawsuits allege that Regeneron made misleading statements about clinical differentiation and slowing event accrual in the Phase 3 fianlimab-Libtayo study, potentially understating the risk that the trial would miss its primary endpoint. The trial failure reportedly erased roughly $11 billion in market value and could create ongoing legal costs, reputational risk, and uncertainty around the program’s commercial prospects. The allegations have not been proven. Hagens Berman Regeneron class-action notice

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $810.24 on Wednesday. The company's 50 day simple moving average is $683.57 and its 200-day simple moving average is $714.66. The firm has a market cap of $83.42 billion, a PE ratio of 20.03, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same quarter in the prior year, the business earned $12.81 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source